U.S. Market for Uterine Fibroid Treatment Is Poised to Reach a Valuation of US $273.6 Mn by the End of 2024 Rising at a CAGR of 2.9%
The uterine fibroid treatment market is driven by growing number of hysterectomy surgeries every year in the country. Furthermore, the rising coverage of healthcare and increasing prevalence of non-cancerous tumors in women of childbearing age is expected to be the most vital reason for expansion of the uterine fibroids market growth. Now a days, fibroids are an important public health concern, due of the large number of women affected by the problem and the large number of hysterectomy procedure are...
View full press release